Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-A1912 + rituximab + gemcitabine + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SHR-A1912 + rituximab + gemcitabine + oxaliplatin is a combination regimen under investigation primarily for treatment of B-cell non-Hodgkin's lymphoma, especially diffuse large B-cell lymphoma (DLBCL). SHR-A1912 is a novel antibody-drug conjugate (ADC) targeting CD79b, a B-cell receptor, linked to a DNA topoisomerase I inhibitor payload. Rituximab is an anti-CD20 monoclonal antibody. Gemcitabine is a nucleoside analog that inhibits DNA synthesis, and oxaliplatin is a platinum-based chemotherapeutic that causes DNA crosslinking and apoptosis. The combination is intended to leverage targeted immunotherapy (with SHR-A1912 and rituximab) and cytotoxic chemotherapy (with gemcitabine and oxaliplatin) for improved efficacy in resistant B-cell malignancies[1][3][5][9][10].
- Other names
- R-GemOx (when referring to rituximab + gemcitabine + oxaliplatin, sometimes called R-GemOx in clinical trials)
02
Targets
CD20 (B-lymphocyte antigen CD20)RNR (Ribonucleotide reductase)B-cell antigen receptor complex-associated protein beta chainTOP1 (DNA Topoisomerase I)DNA
Beyond the preview
Go deeper on SHR-A1912 + rituximab + gemcitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-A1912 + rituximab + gemcitabine + oxaliplatin.